09.15.26 -- The Rise Of South Korea As A Global Biopharma Leader

Rapid deployment of specialized cold chain logistics and cryogenic assets ensures strict temperature compliance, protecting critical research continuity and preventing catastrophic material loss.

Cell and gene therapies offer transformative potential for treating complex diseases, but their manufacturing and global delivery face significant challenges.

Alternative AAV manufacturing approaches can dramatically reduce cost per dose, improve scalability, and increase yields across serotypes, enabling broader patient access to gene therapies.

An in‑depth exploration of why large, precise DNA knock‑ins limit cell therapy progress—and how site‑specific integration enables durable, scalable genetic engineering solutions.

Learn how risk-based studies, quality attributes, and proactive regulatory engagement support confident manufacturing transitions.

Pittsburgh's industrial roots and growing biotech hub unite to scale advanced therapies through new purpose‑built biomanufacturing, automation, and workforce development.

Downstream AAV manufacturing remains a bottleneck, and overcoming it requires platforming that standardizes processes with data-driven CMC systems to improve speed, cost, and program viability.

Discover how Quality by Design strategies can reduce regulatory burden, simplify post-approval changes, and improve lifecycle flexibility while maintaining product quality and supply continuity.

As patented drug revenues drop from 23% to just 10% by 2034, biopharma leaders need a clear framework for matching product strategy to their organization's operating model and risk appetite.

A structured, phase-appropriate regulatory roadmap helps cell therapy developers reduce risk, streamline manufacturing and testing, and avoid costly clinical delays.

Overcome adenoviral scale-up challenges with a design-to-scale manufacturing framework that optimizes cell growth, boosts vector productivity, and supports reliable clinical supply.